News

Eli Lilly (LLY) Secures FDA Label Update for Alzheimer’s Disease Treatment
Eli Lilly and Company (NYSE: LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...
The American Journal of Managed Care2d
FDA Reviewing Sotatercept-csrk Label Expansion for PAH
Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.
CNET1d
The FDA Approved a New Natural Food Dye. Here's How to Avoid the Artificial Ones
The FDA approved the fourth natural food color additive this year, but how can you avoid the artificial dyes still out there?
Becker's Hospital Review6d
FDA OKs label change for Alzheimer’s drug
The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...
Psychiatry Advisor6d
FDA Will Now Require Labeling of ADHD Medication to Indicate Weight Loss Risk
The US Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications.
Precision Medicine Online5d
Eli Lilly's Kisunla Gets New Dosing Schedule in FDA-Approved Labeling Update
The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.